Biofrontera Inc. Names Fred Leffler as Chief Financial Officer
October 24 2022 - 6:45AM
Biofrontera
Inc. (Nasdaq: BFRI),
a biopharmaceutical company specializing in the commercialization
of dermatological products, announces the appointment of Fred
Leffler as Chief Financial Officer, effective immediately. Mr.
Leffler is an experienced financial executive with 15 years of
leadership, financial management, consultancy and operations
experience across a range of private and public organizations,
including growth-stage, private equity and Fortune 100 companies.
Most recently, Mr. Leffler was a Senior Manager
at McKinsey & Company in Boston, having served in a similar
capacity in their Washington, D.C. office earlier in his career.
Previously, he was a Senior Director at FTI Consulting in their
Corporate Finance and Restructuring group, a Vice President at the
boutique global investment firm RockCreek, and held various
financial positions at General Electric and Sun Edison.
“We are delighted to welcome Fred as Chief
Financial Officer during this important period of rapid growth at
Biofrontera. We look forward to drawing upon his expertise to
bolster our financial position in anticipation of growing capital
requirements. Also, Fred’s operational leadership skills will help
us better utilize data-driven approaches to improve our revenue
streams and measure the impact of various strategies and
initiatives,” stated Erica Monaco, Chief Executive Officer of
Biofrontera Inc.
“I am thrilled to be joining the Biofrontera
team. With new products and expanded indications on the horizon to
complement Ameluz growth, I look forward to evaluating and
maximizing all of our potential options. I also look forward to
broadening Biofrontera’s financial community relationships as we
build upon our leadership position in the dermatology market,”
stated Mr. Leffler.
Mr. Leffler received a BSBA in finance and
economics from The Ohio State University Fisher School of Business,
and an MBA from Duke University’s Fuqua School of Business.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on photodynamic therapy (PDT) and topical
antibiotics. The Company’s licensed products are used for the
treatment of actinic keratoses, which are pre-cancerous skin
lesions, as well as impetigo, a bacterial skin infection. For more
information, visit www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the Company’s business and marketing
strategy, future operations and business, potential to expand the
label of Ameluz®, market presence and position of Ameluz® and
ongoing clinical trials conducted by our licensing partners and the
future impact of such trials on the market for Ameluz®. We have
based these forward-looking statements on our current expectations
and projections about future events, nevertheless, actual results
or events could differ materially from the plans, intentions and
expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which
are beyond our control, including, but not limited to, the impact
of extraordinary external events, such as the current COVID-19
pandemic; any changes in the Company’s relationship with its
licensors; the ability of the Company’s licensors to fulfill their
obligations to the Company in a timely manner; the Company’s
ability to achieve and sustain profitability; whether the current
global disruptions in supply chains will impact the Company’s
ability to obtain and distribute its licensed products; changes in
the practices of healthcare providers, including any changes to the
coverage, reimbursement and pricing for procedures using the
Company’s licensed products; the uncertainties inherent in the
initiation and conduct of clinical trials; availability and timing
of data from clinical trials; whether results of earlier clinical
trials or trials of Ameluz® in combination with BF-RhodoLED® in
different disease indications or product applications will be
indicative of the results of ongoing or future trials;
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals; whether the market
opportunity for Ameluz® in combination with BF-RhodoLED® is
consistent with the Company’s expectations; the Company’s ability
to complete the transition to a public company; the Company’s
ability to retain and hire key personnel; the sufficiency of cash
resources and need for additional financing and other factors that
may be disclosed in the Company’s filings with the SEC, which can
be obtained on the SEC website at www.sec.gov. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management's current estimates, projections,
expectations and beliefs. The Company does not plan to update any
such forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Contacts
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Oct 2023 to Oct 2024